Biomerica Inc signs agreement with Beth Israel Deaconess
Biomerica announced that the Company has signed definitive agreements with two of America's leading research institutes to perform the clinical trials needed to validate the performance of its diagnostic-guided therapy,or DGT, to alleviate Irritable Bowel Syndrome symptoms. The Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods, that when removed, may alleviate or improve an individual's IBS symptoms including but not limited to constipation, diarrhea, bloating, pain and indigestion. Importantly, the InFoods DGT can be used without or in conjunction with current pharmacotherapy to potentially improve patient outcomes. Since the InFoods product is a diagnostic guided therapy and not a drug, it has no drug type side effects.